VALIRX PLC — Director's Dealing 2014

Jun 24, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3223K

ValiRx PLC

24 June 2014

24 June 2014

ValiRx Plc

("ValiRx" or "the Company")

Directors' Dealings

The Company was informed on 23 June 2014 that on that date certain directors purchased shares in the Company at a price of 0.31 pence per share, as set out in the table below:-

Director	Number of shares acquired	Total number of shares held subsequent to the acquisition
Satu Vainikka	789,516	23,113,714
Gerry Desler	1,595,968	12,733,921
Seppo Makinen	1,273,387	1,273,387
Kevin Alexander	1,612,903	8,034,843

The issued share capital of the Company comprises 2,921,043,530 ordinary shares of 0.1p per share.

- ENDS -

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka	www.valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson
Daniel Stewart & Company Plc (Broker)	Tel: +44 (0) 20 7776 6550
David Hart
Peckwater PR	Tel: +44 (0) 7879 458 364
Tarquin Edwards	tarquin.edwards@peckwaterpr.co.uk

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiFinn is the biomarkers and diagnostic development division

2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBRGDLBBDBGSX